Comparative Pharmacology
Head-to-head clinical analysis: TEXACORT versus TRIACET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEXACORT versus TRIACET.
TEXACORT vs TRIACET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
Triacetin is a triester of glycerol and acetic acid. Its exact mechanism of action is not fully understood, but it exhibits antifungal activity by disrupting fungal cell membrane integrity and inhibiting fungal growth.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
0.5-1 mg orally three times daily; maximum dose 4 mg/day.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Terminal elimination half-life is approximately 3.5–4 hours in adults with normal renal function; may be prolonged (up to 6–8 hours) in patients with hepatic impairment.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Renal, unchanged drug: <1% of dose; metabolites: approximately 20% in urine, remainder in feces via biliary elimination.
Category C
Category C
Corticosteroid
Corticosteroid